ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
Research output: Contribution to journal › Journal article › Research › peer-review
Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.
| Original language | English |
|---|---|
| Journal | Annals of Oncology |
| Volume | 21 |
| Issue number | 9 |
| Pages (from-to) | 1817-24 |
| Number of pages | 8 |
| ISSN | 0923-7534 |
| DOIs | |
| Publication status | Published - 1 Sep 2010 |
ID: 34097133